The company, which makes drugs in the milk of genetically modified rabbits, said last month it may put itself up for sale and could issue shares to raise cash.
It did not say how much it was paid for the U.S. facilities.
(Reporting by Ben Deighton; Editing by Clarence Fernandez)
Copyright 2013 mojeNovosti.com
web developer: BTGcms